BACE1 and Alzheimer disease: The research reveals that the anticancer agent 6‐thioguanosine (6‐TG) markedly diminishes BACE1 expression without eliciting cytotoxicity while enhancing microglial phagocytic activity, and ameliorate cognitive impairments with reducing Aβ accumulation in AD mice.